The cost-cutting onslaught is a central component of the federal Liberal government’s drive to raise tens of billions of ...

Artificial intelligence has yet to deliver on the most challenging aspect of drug development -- finding new molecules that ...

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

Thank you, Allison, and thanks, everyone, for joining the call today. Adjusted EPS was $1.64, driven by an impressive 5.6% core sales growth, primarily reflecting broad-based strength at Aerospace & ...

BioDlink, a leading global contract development and manufacturing organization (CDMO), has released a white paper titled ...